Last updated April 2026
Peptide Pilot is a personal logging tool. It is not a medical device, does not diagnose or treat any condition, and is not a substitute for professional medical advice, diagnosis, or treatment.
Always consult your physician or another qualified healthcare provider before starting, stopping, or changing any peptide protocol, medication, supplement, diet, or exercise plan.
All dose amounts, reconstitution math, schedules, meals, weights, and measurements are entered by you. The app displays calculations (for example, units per injection from concentration) as a convenience and does not verify, validate, or recommend any dose. You are solely responsible for confirming any number with your healthcare provider.
Peptide Pilot does not send push notifications. Any email reminders we send are best-effort and may be delayed or missed for any reason (mail filtering, deliverability, etc.). Do not rely on Peptide Pilot communications as the sole mechanism for any time-critical medication.
If you think you may have a medical emergency, call 911 (US) or your local emergency number immediately. Do not use this app to report or manage emergencies.
The references below describe the published source of every dose range, schedule preset, and calculation surfaced in the app. They are provided so you can verify the underlying information — they are not a recommendation, prescription, or endorsement of any product or protocol. Every value must still be confirmed with your prescribing clinician before use.
Concentration (mg/mL), draw volume (mL), and U-100 syringe units are computed by direct dimensional analysis from the vial mass, diluent volume, and target dose you enter — there is no proprietary formula. The U-100 syringe convention (100 units = 1 mL) is defined by the U.S. Food & Drug Administration.
Suggested dose chips for Semaglutide, Tirzepatide, and Retatrutide shown in the Add Peptide flow correspond to the dose levels documented in each compound's FDA prescribing information or published clinical trial. They are reproduced solely so users can quickly select a value they have already been prescribed.
The weekly pace selector shown during onboarding (approximately 0.25–1.0 kg / 0.5–2.0 lb per week) reflects the general healthy weight-loss range published by the U.S. Centers for Disease Control and Prevention.
Site-rotation guidance (alternating between abdomen, thigh, and upper arm to reduce lipohypertrophy) follows long-standing subcutaneous-injection best practice as published by the American Diabetes Association.
For questions about this disclaimer or any of the sources above, contact us: